Merrill Conant, MD
Emergency Medicine · Dodge City, KSNPI 1194780445
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $314 and has fallen 60.5% since, to $124 in 2023. Among emergency medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$286
- Novo Nordisk$216
- Lilly USA, LLC$160
- AbbVie$148
- Pfizer$61
- Abbott$51
- plus $297 from 11 others
What the payments were for
- Food & beverage$1,218100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $286 |
| Novo Nordisk | 21 | $216 |
| Lilly USA, LLC | 11 | $160 |
| AbbVie(2 entities) | 9 | $148 |
| Pfizer | 5 | $61 |
| Abbott | 3 | $51 |
| Johnson & Johnson | 3 | $43 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Dexcom, Inc. | 1 | $36 |
| Eisai Inc. | 2 | $30 |
| Novartis | 2 | $30 |
| Merck | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Genentech USA, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
How this compares
$1,218 in reported general payments places this provider in the 95th percentile of 334 emergency medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 51 | $44,880 |
| EliquisApixaban | 84 | $42,720 |
| OzempicSemaglutide | 27 | $23,996 |
| JardianceEmpagliflozin | 22 | $21,305 |
| XareltoRivaroxaban | 36 | $16,242 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $14,807 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $13,760 |
| MyrbetriqMirabegron | 40 | $13,589 |
| FarxigaDapagliflozin Propanediol | 11 | $12,652 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $10,790 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $7,958 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 25 | $7,094 |
| Novolog FlexpenInsulin Aspart | 25 | $5,072 |
| Celecoxib | 28 | $3,567 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $3,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr | $28 | $51,97376 claims |
| PfizerEliquis | $61 | $42,72084 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $286 | $26,41234 claims |
| Novo NordiskOzempic | $216 | $23,99627 claims |
| Johnson & JohnsonXarelto | $43 | $16,24236 claims |
| AbbVieSynthroid | $148 | $1,69015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 emergency medicine providers in Kansas.
Other emergency medicine in Dodge City
- Roger TrotterDodge City$6K
- Joseph WaeckerleOverland Park$266K
- Nima SaraniKansas City$65K
- Nicholas HoseyKansas City$56K
- Chad CannonKansas City$23K
- Andrew PirotteKansas City$2K
- Thomas KreamerOverland Park$2K
- Nathan SmithHays$1K
- Martha FanningOverland Park$1K
- Bradley JacksonKansas City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.